AcelRx Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($1.00) Per Share (ACRX)

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) – Equities researchers at Jefferies Group upped their FY2017 earnings estimates for AcelRx Pharmaceuticals in a research report issued on Tuesday. Jefferies Group analyst M. Andrews now expects that the specialty pharmaceutical company will post earnings per share of ($1.00) for the year, up from their prior estimate of ($1.02). Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for AcelRx Pharmaceuticals’ Q4 2017 earnings at ($0.21) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($0.85) EPS, FY2020 earnings at ($1.14) EPS and FY2021 earnings at ($0.93) EPS.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/11/18/acelrx-pharmaceuticals-inc-forecasted-to-earn-fy2017-earnings-of-1-00-per-share-acrx.html.

Several other research analysts have also weighed in on ACRX. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Roth Capital reiterated a “buy” rating and set a $12.50 price objective on shares of AcelRx Pharmaceuticals in a report on Thursday, August 10th. Finally, Royal Bank Of Canada cut their price objective on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, October 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.83.

AcelRx Pharmaceuticals (ACRX) opened at $2.07 on Thursday. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Perennial Advisors LLC acquired a new stake in AcelRx Pharmaceuticals during the 3rd quarter worth approximately $138,000. Geller Family Office Services LLC acquired a new stake in AcelRx Pharmaceuticals during the 3rd quarter worth approximately $460,000. Bank of New York Mellon Corp increased its position in AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after purchasing an additional 6,942 shares in the last quarter. Virtu KCG Holdings LLC increased its position in AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 101,742 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in AcelRx Pharmaceuticals during the 2nd quarter worth approximately $319,000. 23.09% of the stock is owned by hedge funds and other institutional investors.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $1.90 per share, with a total value of $57,000.00. Following the transaction, the director now owns 150,000 shares in the company, valued at $285,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total transaction of $53,751.69. Following the sale, the insider now directly owns 16,379 shares of the company’s stock, valued at approximately $86,644.91. The disclosure for this sale can be found here. In the last three months, insiders have purchased 72,000 shares of company stock valued at $178,980. Corporate insiders own 28.10% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply